These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29875061)

  • 1. The anaemia control model: Does it help nephrologists in therapeutic decision-making in the management of anaemia?
    Bucalo ML; Barbieri C; Roca S; Ion Titapiccolo J; Ros Romero MS; Ramos R; Albaladejo M; Manzano D; Mari F; Molina M
    Nefrologia (Engl Ed); 2018; 38(5):491-502. PubMed ID: 29875061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients.
    Barbieri C; Molina M; Ponce P; Tothova M; Cattinelli I; Ion Titapiccolo J; Mari F; Amato C; Leipold F; Wehmeyer W; Stuard S; Stopper A; Canaud B
    Kidney Int; 2016 Aug; 90(2):422-429. PubMed ID: 27262365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.
    Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C
    Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience.
    Jesus-Silva JA; Lamplugh A; Dhada S; Burton JO; Bhandari S
    BMC Nephrol; 2020 Jun; 21(1):212. PubMed ID: 32493240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
    Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
    Rao A; Gilg J; Williams A
    Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
    Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
    Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of response to various erythropoiesis--stimulating proteins using anemia management software.
    Waterschoot M
    J Ren Care; 2007; 33(2):78-82. PubMed ID: 17702511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
    Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
    J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin stability and patient compliance with darbepoetin alfa in peritoneal dialysis patients after the implementation of the prospective payment system.
    Pirkle JL; Paoli CJ; Russell G; Petersen J; Burkart J
    Clin Ther; 2014 Nov; 36(11):1665-74. PubMed ID: 25256386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
    Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
    Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
    Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
    Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of postpartum anaemia screening to improve anaemia diagnosis and patient care: A prospective non-randomized before-and-after anaemia screening protocol implementation study.
    Yefet E; Suleiman A; Garmi G; Hatokay A; Nachum Z
    Sci Rep; 2019 May; 9(1):7810. PubMed ID: 31127175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.